SCHEMBL24812935

SCHEMBL24812935

C[C@H](OCc1ccc(F)cc1)[C@H](N)C(N)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.44
PARP10 Q53GL7 1/20 0.44
IDO1 P14902 2/20 0.42
AGXT P21549 2/20 0.42
MAOA P21397 1/20 0.40
TSHR P16473 1/20 0.40
SLC1A3 P43003 2/20 0.40
SLC1A2 P43004 2/20 0.40
SLC1A1 P43005 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
LMNA P02545 1/20 0.39
NR4A2 P43354 1/20 0.39
HPGD P15428 1/20 0.39
EPHX1 P07099 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30708047 1.00 MAOB (0.44) MAOBPARP10IDO1AGXTMAOA
SCHEMBL4239549 0.84 SLC1A3 (0.57) PARP10TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL8236018 0.84 SLC1A3 (0.57) PARP10TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL29980108 0.84 KMT2A (0.39) MAOBPARP10IDO1AGXTTSHR
SCHEMBL26907849 0.84 KMT2A (0.39) MAOBPARP10IDO1AGXTTSHR
SCHEMBL24814073 0.79 ACACB (0.42) MAOBPARP10TSHRKMT2AMEN1
SCHEMBL25139795 0.77 TSHR (0.41) MAOBPARP10TSHRKMT2AMEN1
SCHEMBL25139879 0.76 TDP1 (0.42) MAOBPARP10TSHRKMT2AMEN1
SCHEMBL21587147 0.76 IDO1 (0.48) MAOBIDO1AGXTKMT2AMEN1
SCHEMBL8781581 0.76 IDO1 (0.54) MAOBPARP10IDO1AGXTMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4358954-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2024-05-01 EP disclosed
CN-117561058-A CDK2 inhibitors and methods of use thereof 塞迪拉治疗股份有限公司 2024-02-13 CN disclosed
US-20230121337-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. 2023-04-20 US disclosed
WO-2022272106-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2022-12-29 WO disclosed
WO-2022272106-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2022-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121337-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK20, CDK2AP2 MAOB 2610/4885PARP10 875/4885IDO1 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.